Manufacturing in the modern pharmaceutical era has become increasingly challenging to control, especially when dealing with live organisms. This increase in process complexity has resulted in high variability experiments and unexpected outcomes that result in significant production inefficiencies. Being able to anticipate the performance of a process before it has ended can be of immense value for any manufacturing team. This can enable pharmaceutical companies to significantly improve yield output and drastically reduce manufacturing costs for any given process.
Bigfinite’s AI-powered, GxP-qualified platform offers a range of functionalities that allow for the creation of a fully adaptable, real-time solution to help production teams anticipate bioreactors’ poor performance and as a result, achieve higher product quality.